Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
28 févr. 2023 16h01 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it...
Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023
09 janv. 2023 08h30 HE
|
Alaunos Therapeutics, Inc.
Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platformIncreasing patient enrollment to...
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
29 nov. 2022 09h01 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing...
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock
28 nov. 2022 16h01 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has...
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
14 nov. 2022 07h00 HE
|
Alaunos Therapeutics, Inc.
Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer...
Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
08 nov. 2022 08h30 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended...
Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting
07 nov. 2022 08h00 HE
|
Alaunos Therapeutics, Inc.
Data supports high-throughput screening process to identify neoantigen-reactive TCRsExclusive ownership of discovered KRAS mutation-reactive TCRshunTR enables expansion of the Company’s hotspot...
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
21 sept. 2022 08h30 HE
|
Alaunos Therapeutics, Inc.
First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusionSleeping Beauty TCR-T cell therapy had a manageable safety...
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September
07 sept. 2022 08h30 HE
|
Alaunos Therapeutics, Inc.
HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S....
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy
06 sept. 2022 08h00 HE
|
Alaunos Therapeutics, Inc.
First patient dosed achieved a confirmed objective partial response Second patient dosed at second dose level; cleared 28-day safety windowData to be presented on Friday, September 30 at 8:30am ET in...